Tag Archives: Family Office

Hot Investor Mandate 1: West Coast-Based Family Office Invests Up to $10M Into Early-Stage Therapeutics, Devices, and Tools Companies

31 May

A family office based in the West Coast invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Family Office with USA and UK Offices Seeks to Invest Up to $5M in Early-Stage Therapeutics Companies with Preference for Platform Technologies

24 May

A family office investment vehicle with offices in the USA and UK is looking to provide equity capital to USA-based therapeutic companies. The firm usually invests in Series A or B rounds, and will consider to participate in a seed round of financing. The firms typical deal size is variable, generally going as high as $5 million for an initial investment.

The firm is currently looking for companies developing Therapeutics. The firm is opportunistic in terms of sub-sector and indication though they do have a preference for companies with platform technologies. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials. The firm’s portfolio includes oncology, the microbiome, pain, neurological and rare diseases biotech companies.

The firm looks to invest in companies with experienced management teams. The firm is capable to act as either a lead or a co-lead investor and generally seeks board or board observer rights. As a pro-active investor, the firm will assist in the growth of a company, recruit new talents, develop preclinical, clinical and IP strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Firm Partnered with a Family Office Seeking to Provide Seed Capital to USA-Based Therapeutics Opportunities

17 May

A Chicago-based life sciences investment fund is focused on accelerating the growth of early-stage biotechnology and pharmaceutical companies. Partnered with a family investment office, the firm seeks to make 10 seed round investments within the next year. The firm will invest in companies based in the U.S.

The firm is seeking investments in biotech/therapeutics companies and is not interested in medical device or digital health technologies. The firm is interested in companies with assets or platform technologies in preclinical or early clinical development and is indication agnostic.

The firm does not have any company management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: